Jérémy Guillot

Jérémy Guillot

Auto-generated profile, based on publicly available information

Jérémy Guillot

Swiss Institute for Experimental Cancer Research (ISREC), EPFL, Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in Science
Verified
Journal Article
Closed access
QZQiqun Zeng
Qiqun Zeng
SSSadegh Saghafinia
Sadegh Saghafinia
ACAgnieszka Chryplewicz
Agnieszka Chryplewicz
NFNadine Fournier
Nadine Fournier
LCLucine Christe
Lucine Christe
DHDouglas Hanahan
Douglas Hanahan
Many human cancers manifest the capability to circumvent attack by the adaptive immune system. In this work, we identified a component of immune evasion that involves frequent up-regulation of fragile X mental retardation protein (FMRP) in solid tumors. FMRP represses immune attack, as revealed by cancer cells engineered to lack its expression. FMRP-deficient tumors were infiltrated by activated T cells that impaired tumor growth and enhanced survival in mice. Mechanistically, FMRP’s immunosuppression was multifactorial, involving repression of the chemoattractant C-C motif chemokine ligand 7 (CCL7) concomitant with up-regulation of three immunomodulators—interleukin-33 (IL-33), tumor-secreted protein S (PROS1), and extracellular vesicles. Gene signatures associate FMRP’s cancer network with poor prognosis and response to therapy in cancer patients. Collectively, FMRP is implicated as a regulator that orchestrates a multifaceted barrier to antitumor immune responses.

27 April 2025 in Cancer Discovery
Verified
Journal Article
Open access
MLMorgane Lecointre
Morgane Lecointre
JGJérémy Guillot
Jérémy Guillot
RMRachel Marcone
Rachel Marcone
DODilara Ozdoganlar
Dilara Ozdoganlar
MCMarjorie Cayatte
Marjorie Cayatte
DHDouglas Hanahan
Douglas Hanahan
It is well-established that symptomatic cancers evade immune destruction by coalescing tumor microenvironments to suppress adaptive immunity. Additionally, mouse models of cervical and other cancers have revealed a capability of tumors to systemically induce the expansion of neutrophils that cripple T-cell development in spleen and lymph nodes, further impairing immune responses. Now we show that human papillomavirus type 16 (HPV16)–driven squamous cell tumors in the cervix and skin release into the circulatory system four immunoregulatory ligands – IL-1α, IL-1β, IL-33, and IL-36β – that bias the bone marrow toward granulocytic myelopoiesis, producing immunosuppressive neutrophils populating spleens and tumors. An IL-1 family coreceptor antagonist, anti-IL1RAP, abrogates this neutrophil expansion and complements an otherwise inefficacious HPV16 E7 peptide vaccine to elicit an effective antitumor immune response that is further sustained by anti–CTLA-4. Evidence for similarly IL-1–driven systemic immunosuppression in human cervical tumors encourages evaluation of this combinatorial therapeutic strategy for treating a largely immunoevasive cancer type. Significance: Cervical cancer is the fourth leading cause of cancer deaths in women worldwide. Although the disease is driven by two antigenic viral oncoproteins, therapeutic vaccines have proved ineffective, inferentially due to systemic immunosuppression. This study elucidated an actionable mechanism, whose disruption renders an oncoprotein vaccine efficacious, with translational potential.

28 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JGJérémy Guillot
Jérémy Guillot
CDChloé Dominici
Chloé Dominici
ALAdrien Lucchesi
Adrien Lucchesi
TNThi Trang Huyen Nguyen
Thi Trang Huyen Nguyen
JNJérémy Nigri
Jérémy Nigri
FMFanny Mann
Fanny Mann
Recent evidence has highlighted the presence of neuronal nerve processes in the tumor microenvironment. However, the origin of intra-tumoral nerves remains poorly known, in part because of technical difficulties in tracing nerve fibers via regular histological preparations. Here, we employed three-dimensional (3D) imaging of cleared tissues for a comprehensive analysis of sympathetic innervation in pancreatic ductal adenocarcinoma (PDAC). The results support two independent, but coexisting, mechanisms: passive engulfment of pre-existing nerves within tumors and active, localized sprouting of nerve terminals into non-neoplastic lesions and tumor periphery. Nerve ablation revealed an inverse correlation between sympathetic innervation and tumor growth and spread. Furthermore, sympathectomy increased CD163 + macrophage levels, which contributed to worse outcomes. Altogether, our findings revealed protective properties of the sympathetic nervous system in PDAC immunity and progression that could pave the way for new treatments.

3 July 2025
Verified
Other
Open access
PDF file
MLMorgane Lecointre
Morgane Lecointre
JGJérémy Guillot
Jérémy Guillot
RMRachel Marcone
Rachel Marcone
DODilara Ozdoganlar
Dilara Ozdoganlar
MCMarjorie Cayatte
Marjorie Cayatte
DHDouglas Hanahan
Douglas Hanahan
IL1RAP expression profile, and analysis of myeloid, T cell, and cancer cell populations upon anti-IL1RAP treatment.

3 July 2025
Verified
Other
Open access
MLMorgane Lecointre
Morgane Lecointre
JGJérémy Guillot
Jérémy Guillot
RMRachel Marcone
Rachel Marcone
DODilara Ozdoganlar
Dilara Ozdoganlar
MCMarjorie Cayatte
Marjorie Cayatte
DHDouglas Hanahan
Douglas Hanahan
It is well-established that symptomatic cancers evade immune destruction by coalescing tumor microenvironments to suppress adaptive immunity. Additionally, mouse models of cervical and other cancers have revealed a capability of tumors to systemically induce the expansion of neutrophils that cripple T-cell development in spleen and lymph nodes, further impairing immune responses. Now we show that human papillomavirus type 16 (HPV16)–driven squamous cell tumors in the cervix and skin release into the circulatory system four immunoregulatory ligands – IL-1α, IL-1β, IL-33, and IL-36β – that bias the bone marrow toward granulocytic myelopoiesis, producing immunosuppressive neutrophils populating spleens and tumors. An IL-1 family coreceptor antagonist, anti-IL1RAP, abrogates this neutrophil expansion and complements an otherwise inefficacious HPV16 E7 peptide vaccine to elicit an effective antitumor immune response that is further sustained by anti–CTLA-4. Evidence for similarly IL-1–driven systemic immunosuppression in human cervical tumors encourages evaluation of this combinatorial therapeutic strategy for treating a largely immunoevasive cancer type.Significance:Cervical cancer is the fourth leading cause of cancer deaths in women worldwide. Although the disease is driven by two antigenic viral oncoproteins, therapeutic vaccines have proved ineffective, inferentially due to systemic immunosuppression. This study elucidated an actionable mechanism, whose disruption renders an oncoprotein vaccine efficacious, with translational potential.

3 July 2025
Verified
Other
Open access
PDF file
MLMorgane Lecointre
Morgane Lecointre
JGJérémy Guillot
Jérémy Guillot
RMRachel Marcone
Rachel Marcone
DODilara Ozdoganlar
Dilara Ozdoganlar
MCMarjorie Cayatte
Marjorie Cayatte
DHDouglas Hanahan
Douglas Hanahan
IL1RAP blockade increases the proportion of neutrophils expressing antigen presentation-related markers.